



ABN 82 010 975 612

Level 18, 101 Collins Street  
Victoria 3000 Australia  
Telephone: + 61 7 3273 9133  
Facsimile: + 61 7 3375 1168  
[www.tbgbio.com](http://www.tbgbio.com)

29 July 2021

## **ASX Announcement Restatement of FY2020 Financial Statements**

In the course of preparing its 2021 Interim Report for the Half-Year ended 30 June 2021 (Interim Financial Statements), TBG Diagnostics Limited (the “**Company**”) has identified that further disclosure is required to be made in its 31 December 2020 Financial Statements, in relation to its restructuring activities involving the sale of shares held by the Company in its subsidiary company, TBG Inc. and other related restructuring transactions that occurred after 31 December 2020 but prior to 30 March 2021.

The Company has decided to restate its FY2020 Financial Statements to include further disclosures in relation to the following transactions and restructuring activities:

- **The establishment of new subsidiary entities of TBG Inc., being TBG Trading Co (HK) Ltd (“TBG Trading”) and TBG Enterprise Management (Xiamen) Co Ltd (“TBG Management”) in January 2021**

On 11 January 2021, TBG Inc. established a wholly-owned subsidiary, TBG Trading and then a next tier wholly-owned subsidiary, TBG Management, to TBG Trading on January 28, 2021.

TBG Trading was renamed U-GEN Biotechnology (HK) Company Limited on 11 June 2021.

- **The disposal of the Company’s 53.35% equity in TBG Inc. in March 2021**

In March 2021, TDL entered into various agreements with TBG Xiamen’s shareholders to sell 53.35% of the equity in TBG Inc.

- **The acquisition of control of a 51% equity interest of Hunan Da Di Tong Nian (“DDTN”) by TBG Management through contractual arrangements in March 2021**

In March 2021, TBG Management entered into contractual arrangements with DDTN and the shareholders of DDTN to acquire control of a 51% of the equity interest of DDTN.

- **The acquisition by TBG Inc. of 50% of the equity of Precision Medicine (HK) Co. Ltd (“HKPMC”) in March 2021**

On 3 March 2021, TBG Inc entered into an agreement to acquire 50% of the equity of HKPMC.

HKPMC is a HK regional government certified special lab that provides a range of precision diagnostics services, such as histopathology, cytopathology, molecular pathology and innovation nano-biomarker investigation.

- **The acquisition by TBG Inc. of 50% of the equity of Advanced Medimaterial Biotech (AMB) Co. Ltd (“AMB”)**

On 29 March 2021, TBG Inc entered into an agreement to acquired 50% of the equity of AMB.

AMB owns a semiconductor manufacturing process to produce innovative magnetic beads that can be used for multiplex molecular or immune assays. This platform can develop a range of very powerful tools for detecting genetic, proteomic, or other pathogenic molecular substances in the body fluid, and is playing a vital role for personalized precision medicine.

Further information will be provided in the restated FY2020 Financial Statements which will be released to the market in due course.

Authorised by:

Jitto Arulampalam  
Chairman